Interventions Testing Program

Overview

The Interventions Testing Program is the mouse-longevity research project used in Supplements for Longevity & Their Efficacy | Dr. Peter Attia as a comparatively rigorous test of whether candidate interventions change lifespan rather than only pathways or biomarkers.

Current Profile

Within the source, the program matters less as a catalog of compounds than as an evidence standard. Survival results in mice are used to challenge claims built from mechanism, unusual disease models, or subjective response. Peter Attia contrasts negative reported results for NR and resveratrol with positive results for rapamycin, canagliflozin, acarbose, and 17-alpha estradiol.

The program is still preclinical. A mouse lifespan result can strengthen or weaken a longevity hypothesis, but it does not establish human benefit, dose, safety, indication, or treatment eligibility.

Key Characteristics

• Tests candidate longevity interventions against survival and healthspan-relevant outcomes in mice.
• Is presented in the source as a stronger filter than mechanism-only reasoning or a single unusual disease model.
• Distinguishes interventions that change mouse lifespan from those that do not in the tested conditions.
• Produces preclinical evidence that still requires human translation.

Evidence

• Design role: Supplements for Longevity & Their Efficacy | Dr. Peter Attia describes the program as the strongest available non-human testing system for candidate lifespan interventions.
• Discriminating results: Supplements for Longevity & Their Efficacy | Dr. Peter Attia reports negative results for NR and resveratrol and positive results for rapamycin, canagliflozin, acarbose, and 17-alpha estradiol.
• Evidence boundary: Supplements for Longevity & Their Efficacy | Dr. Peter Attia uses those results to reject a direct jump from pathway plausibility to human longevity advice.

Qualifications

This profile is bounded to one podcast source and is not an independent review of program protocols, every tested dose, sex-specific result, replication record, healthspan measure, or publication. Mouse survival evidence is informative but cannot by itself establish human clinical efficacy or safety.

What Changed

• Established the program as the wiki’s project-level reference for rigorous preclinical longevity testing.

Relationships

• Mechanism-to-Outcome Evidence Hierarchy - evidence framework the program exemplifies for longevity claims.
• NAD Therapy Evidence Boundary - intervention boundary strengthened by the reported negative NR result.
• Peter Attia - guest who uses the program as his principal non-human longevity benchmark.
• Huberman Lab - show context in which the program is explained.